MedPath

Liver Transplantation Versus Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis

Not Applicable
Completed
Conditions
Cirrhosis
Interventions
Procedure: liver transplantation
Other: standard care for liver disease
Registration Number
NCT00701792
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Brief Summary

Liver transplantation has been universally recognized to improve survival of patients suffering from end-stage (Pugh C) alcoholic cirrhosis. However, for Pugh B patients, the benefit of liver transplantation remains to be demonstrated. The aim of the present study was to compare the outcome of Pugh B patients with alcoholic cirrhosis randomly assigned for immediate liver transplantation (group 1) or standard treatments (group 2).

Detailed Description

120 patients (60 per group) were included. The therapeutic strategy defined by randomization was achieved in 68% of group 1 patients and 75% of group 2 patients (NS). All-causes death and cirrhosis-related death were not different in group 1 and group 2 patients: the five-year survival rate was 58% in group 1 and 69% in group 2 patients (NS). Through multivariate analysis, the independent predictors of long-term survival were absence of ongoing alcohol consumption (p\<0.001), recovery from Pugh C (p=0.046), and baseline Pugh score\<8 (p=0.029). Liver transplantation was associated with a higher rate of de novo malignancies (30.4% vs. 7.8%, OR=5.1, p=0.001).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • cirrhosis
  • age 18-65yrs
  • Pugh B
  • written consent
Exclusion Criteria
  • HIV, HBV or HCV infection
  • hepatocellular carcinoma
  • Pugh A or Pugh C cirrhosis
  • creatinin >200µMol/L
  • sepsis
  • psychiatric disorders
  • extrahepatic neoplasia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1liver transplantationsurgery : liver transplantation
2standard care for liver diseasestandard care for liver disease
Primary Outcome Measures
NameTimeMethod
all causes mortalityfive years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (13)

service d'hépatologie CHU jean Minjoz

🇫🇷

Besancon, France

CHRU CAEN - Service d'hépato-gastroentérologie

🇫🇷

Caen, France

Hépato-gastroenterologie CHU Bocage

🇫🇷

Dijon, France

Centre d'épidémiologie de population EPI 106

🇫🇷

Dijon, France

Hôpital Bon secours - Hépato-gastroentérologie

🇫🇷

Metz, France

Hepato-gastroenterologie

🇫🇷

Poitiers, France

CHU Reims - hépato-gestroentérologie

🇫🇷

Reims, France

Clinique des maladies du foie Hôpital Pontchailloux

🇫🇷

Rennes, France

Hôpital Pitié-Salpétrière - Hépato-gastroentérologie

🇫🇷

Paris, France

Hôpital Purpan - Hépato-gastroentérologie

🇫🇷

Toulouse, France

CHU Henri Mondor - Hépato-gastroentérologie

🇫🇷

Creteil, France

Hôpital Beaujon - Hépato-gastroentérologie

🇫🇷

Clichy, France

Hôpital Saint-Eloi - Hépato-gastroentérologie

🇫🇷

Montpellier, France

© Copyright 2025. All Rights Reserved by MedPath